About Us
Our Company
Management & Board
Aceragen
Tilsotolimod
Toll-Like Receptor Activation
Publications & Presentations
Investor Relations
×
A Phase 1-2 study to evaluate the safety and efficacy of intratumoral injection of the TLR9 agonist tilsotolimod in combination with ipilimumab in PD-1 inhibitor refractory MM
